About Jeffrey Barnes, MD, PhD

Jeffrey Barnes, MD, PhD is a graduate of the University of Illnois College of Medicine. He completed his residency in Internal Medicine at the Beth Israel Deaconess Medical Center in Boston. He then completed his fellowship in Medical Oncology at the Dana Farber Cancer Institute before joining the faculty at the Massachusetts General Hospital. He is a member of the US Cutaneous Lymphoma Consortium. His research interests focus on the identification and evaluation of novel agents for the treatment of lymphoma.

Clinical Interests:

Treats:

Locations

Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-724-4000
Fax: 617-726-8330

Martha's Vineyard Hospital
1 Hospital Rd.
Oak Bluffs, MA 02557
Phone: 508-693-0410

Mass General Cancer Center at Newton-Wellesley
2014 Washington St.
Newton, MA 02462
Phone: 617-219-1230

Medical Education

  • , University of Illinois College of Medicine at Urbana-Champaign
  • Fellowship, Dana Farber Cancer Institute

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Barnes performs translational research in lymphoma including clinical trials of novel therapies for the treatment of cutaneous lymphoma, non-Hodgkin lymphomas, Hodgkin lymphoma (Hodgkin's disease), and chronic lymphocytic leukemia.

Publications

  • Select Publications:

    • Barnes JA, Abramson JS. Differential Diagnosis and Novel Treatment Strategies for Adult T Cell Leukemia Lymphoma. Oncology. Dec 23;14, p.1267-1270 (2009)
    • Abramson JS, Hellmann M, Barnes JA, Hammermann P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP. Intravenous methotrexate as central nervous system prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer Jun 8 Epub ahead of print (2010)
    • Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuburg D, Tomey C, Hochberg EP, Canellos GP, Abramson JS. End of treatment but not interim PET scan predicts outcomes in non-bulky limited stage Hodgkin lymphoma. Ann of Oncology  Oct 15 (2010)
    • Barnes JA, LaCasce AS, Feng Y, Tomey C, Neuburg D, Michaelson JS, Hochberg EP, Abramson JS. Evaluation of the Addition of Rituximab to CODOX-M/IVAC for Burkitt Lymphoma: A Retrospective Analysis. Ann of Oncology In Feb 21 (2011)

Reviews: Comments and Ratings

4.9out of 5(375 Ratings, 146 Comments)

February 2025

Dr. Barnes is an excellent doctor and he takes care very, very, very good care of everybody.


February 2025

Very knowledgeable, professional, understanding and kind. Wish all providers could be like him.


February 2025

First time seeing this provider as he replaced my previous oncologist and felt very comfortable with him from the start. I felt he was very knowledgeable in his field, reviewed all of my prior records and was a physician who listened and you could talk to.


February 2025

This was my first visit with Dr. Barnes. I was very impressed. He knew all about my CLL. I learned more about my condition from him.For example, I I learned that CLL is a type of Lymphoma which I found very interesting. Dr. Barnes also gave me great news! I have been in remission for five years, and Dr. Barnes informed me that I, possibly, could ... Read More


February 2025

I find Dr. Barnes to be very thorough, informative, and very positive in his delivery. It's not always the most easy information, so I would highly recommend him.


February 2025

He was encouraging, and spoke in simple straightforward language easy for a lay person to understand


February 2025

Excellent


February 2025

I arrived early and was taken in very soon afterwards. My doctor was very attentive and listened carefully to what I had to say.


February 2025

I felt well cared for. All of my questions were answered.


February 2025

The doctor is new to me, as Dr. Ernst retired. Personable, seems to be a good technician.

View More
Ratings and Comments Powered by NRC Health